Home › SEC Filings › Insider Cluster Activity
Insider Cluster Activity
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CGEN | CLUSTER | neutral | 2/10 | Two insiders at Compugen (CGEN) sold shares totaling ~$22K after exercising stock options. The dollar amount represents | Apr 27, 2026 |
| HEPA | CLUSTER | mixed | 6/10 | Two corporate insiders at Hepion Pharmaceuticals, including the Interim CEO, purchased $100,000 worth of shares in open- | Apr 27, 2026 |
| NTHI | CLUSTER | mixed | 6/10 | Two C-suite executives at NEONC Technologies Holdings purchased shares in the open market, totaling $51,000, amid a peri | Apr 24, 2026 |
| KYMR | CLUSTER | neutral | 3/10 | Two insiders at Kymera Therapeutics sold a combined $315K in shares within a 7-day window, including COO Chadwick Jeremy | Apr 24, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | Three key insiders at United Therapeutics, including CEO Martine Rothblatt, CFO James Edgemon, and Director Christopher | Apr 24, 2026 |
| IMVT | CLUSTER | neutral | 3/10 | Two C-suite executives at Immunovant, the CFO and CTO, sold shares worth $845,000 in open-market transactions on April 2 | Apr 24, 2026 |
| SRRK | CLUSTER | bearish | 7/10 | Four senior executives at Scholar Rock, including the CEO, CFO, and other C-suite leaders, sold shares worth $3.15 milli | Apr 24, 2026 |
| PHVS | CLUSTER | bearish | 5/10 | Four corporate insiders at Pharvaris N.V. (PHVS) sold shares in a concentrated 7-day window, including CEO Berndt Modig | Apr 24, 2026 |
| PHVS | CLUSTER | neutral | 3/10 | Two C-suite executives at Pharvaris sold shares in the past week, including CEO Modig Berndt and CMO Lu Peng, generating | Apr 24, 2026 |
| SGMO | CLUSTER | neutral | 3/10 | Two senior executives at Sangamo Therapeutics, the Chief Development Officer and Head of Research & Technology, sold sha | Apr 23, 2026 |
| DYN | CLUSTER | bearish | 6/10 | Two directors at Dyne Therapeutics (DYN) sold over $11.4 million in shares over the past 7 days, including a $4.3 millio | Apr 23, 2026 |
| TWST | CLUSTER | neutral | 4/10 | Twist Bioscience CEO Emily Leproust and CFO Adam Laponis sold a combined $345K in shares over the past week, with the ma | Apr 23, 2026 |
| TVTX | CLUSTER | bearish | 7/10 | Five executives at Travere Therapeutics, including the CEO, CFO, and CMO, sold shares in a coordinated cluster totaling | Apr 23, 2026 |
| BCAX | CLUSTER | neutral | 5/10 | Three top executives at Bicara Therapeutics, including the CEO, CFO, and President/COO, collectively sold $750K worth of | Apr 22, 2026 |
| UTHR | CLUSTER | bearish | 6/10 | Four corporate insiders at United Therapeutics, including the CEO, CFO, and General Counsel, conducted open-market share | Apr 22, 2026 |
| ALMR | CLUSTER | bullish | 7/10 | Alamar Biosciences insiders and a major shareholder jointly purchased $8 million in stock, with Director Naclerio and 10 | Apr 22, 2026 |
| KLRA | CLUSTER | bullish | 9/10 | Four major insiders at Kailera Therapeutics, including two directors and two 10% owners, collectively purchased $326.75 | Apr 22, 2026 |
| KLRA | CLUSTER | bullish | 8/10 | Multiple 10% owners and directors of Kailera Therapeutics (KLRA) collectively purchased $318.75 million in stock over a | Apr 22, 2026 |
| SION | CLUSTER | bearish | 6/10 | Two company insiders, both directors, sold shares in a concentrated 7-day window, totaling $12.63 million in open-market | Apr 21, 2026 |
| LQDA | CLUSTER | bearish | 7/10 | Eight corporate insiders at Liquidia Corp, including the CEO, CFO, and multiple C-suite executives, sold shares in a con | Apr 21, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | Four corporate insiders at United Therapeutics, including the CEO, CFO, and General Counsel, sold shares in open-market | Apr 21, 2026 |
| ALMR | CLUSTER | bullish | 7/10 | Two insiders at Alamar Biosciences, Inc. (ALMR), Director Nicholas Naclerio and 10% owner Illumina Innovation Fund II GP | Apr 20, 2026 |
| KALV | CLUSTER | bearish | 6/10 | KalVista Pharmaceuticals executives Palleiko (CEO) and Piekos (CFO) sold shares worth $231K in aggregate over a 7-day wi | Apr 20, 2026 |
| BCAX | CLUSTER | bearish | 7/10 | Bicara Therapeutics executives Claire Mazumdar (CEO) and Ryan Cohlhepp (President/COO) sold a combined $538,203 worth of | Apr 20, 2026 |
| SRRK | CLUSTER | bearish | 6/10 | The CEO and CFO of Scholar Rock sold a combined $2.03 million in shares through open-market transactions on April 16, 20 | Apr 20, 2026 |
| KLRA | CLUSTER | bullish | 8/10 | Two insiders, including a director and major shareholder, collectively purchased $159.38 million of Kailera Therapeutics | Apr 20, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | Four insiders at United Therapeutics, including CEO Martine Rothblatt and CFO James Edgemon, conducted open-market share | Apr 20, 2026 |
| CGTX | CLUSTER | bullish | 5/10 | Two C-suite executives at Cognition Therapeutics (CGTX), the CEO and Chief Medical Officer, purchased shares in the open | Apr 20, 2026 |
| BLTE | CLUSTER | bearish | 7/10 | Four insiders at Belite Bio, including the CEO, CFO, and Chief Scientific Officer, sold shares in a coordinated cluster | Apr 20, 2026 |
| SCLX | CLUSTER | mixed | 6/10 | Scilex Holding Co (SCLX) insiders showed mixed activity: CEO Ji Henry sold $100K and earlier bought $500K in shares, whi | Apr 20, 2026 |